4D pharma plc: 4D Pharma to Participate in Upcoming Cantor Fitzgerald Microbiome Leaders Panel
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) a novel class of drug derived from the microbiome, today announces Duncan Peyton, Chief Executive Officer of 4D pharma, will participate in Cantor Fitzgerald's virtual panel, titled "Microbiome Players with Guided Readouts in 2021," on Thursday, February 18, 2021 at 15:00 GMT (10:00 ET).
A webcast of the panel will be available via the "Events" section of the 4D pharma website at www.4dpharmaplc.com.
About 4D pharma
Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.